| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -55,355 | -40,784 |
| Share based compensation | -228 | 187 |
| Impairment of long-lived assets | 4,667 | - |
| Depreciation and amortization | 4,936 | 4,035 |
| Non-cash lease expenses | 3,108 | 1,659 |
| Unrealized foreign exchange loss | -3,683 | -4,869 |
| Change in contingent consideration | -322 | -339 |
| Non-cash interest expense | 38 | 25 |
| Deferred tax benefit | -118 | -47 |
| Profit on sale of property and equipment | 349 | 281 |
| Contract asset (including related parties) | 0 | - |
| Prepaid expenses and other current assets | -426 | 531 |
| Research and development incentives receivable | -2,946 | -3,091 |
| Accounts payable | -1,854 | -813 |
| Accrued expenses and other current liabilities | -3,340 | -2,767 |
| Deferred income | -498 | -342 |
| Operating lease liabilities | -1,477 | -973 |
| Net cash used in operating activities | -43,737 | -33,011 |
| Proceeds from sale of property and equipment | 451 | - |
| Purchases of property and equipment | 37 | 37 |
| Net cash provided by/(used) in investing activities | 414 | -37 |
| Proceeds from issue of ordinary shares, net of issuance costs | 0 | 0 |
| Issue of shares from the exercise of stock options | 2 | 2 |
| Net cash provided by financing activities | 2 | 2 |
| Effect of exchange rates on cash, cash equivalents and restricted cash | 6,595 | 8,430 |
| Net decrease in cash, cash equivalents and restricted cash | -36,726 | -24,616 |
| Cash and cash equivalents at beginning of period | 112,400 | - |
| Cash and cash equivalents at end of period | 75,674 | - |
Barinthus Biotherapeutics plc. (BRNS)
Barinthus Biotherapeutics plc. (BRNS)